Exploring small-molecular-mass inhibitors of the enzyme acetylcholinesterase to slow the breakdown of the neurotransmitter acetylcholine presents the mainstream direction for Alzheimer’s disease treatment [82]. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.